IND for iCo

Article

iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.

iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.

iCo-007, for the treatment of eye diseases such as age-related macular degeneration and diabetic retinopathy, is a second generation drug that inhibits the production of c-Raf kinase, an enzyme associated with the development of new blood vessels in the eye.

Isis will receive a milestone payment from iCo based on the IND filing.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
Syringe in front of DNA helix strands. Concept image for gene therapy for retinal diseases including retinitis pigmentosa and Stargardt Disease. Image credit: ©Corona Borealis – stock.adobe.com

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

Hattie Hayes
May 13th 2025
Article

The company shared results from the AAVB-081 clinical programme and AAVB-039 preclinical programme at ARVO

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A series of kidney scans. Concept image for retinal biomarker scan, kidney function, lupus and autoimmune disease. Image credit: ©Sved Oliver – stock.adobe.com

Retinal microvascular changes in patients with systemic lupus erythematosus: Importance of OCTA

Lynda Charters
May 12th 2025
Article

The biomarkers are especially crucial for patients with lupus nephritis

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Bausch + Lomb website on phone and computer Image credit: AdobeStock/Timon

Bausch + Lomb's LuxLife IOL receives CE Mark approval

Jordana Joy
May 8th 2025
Article

The LuxLife full range of vision intraocular lens is available in a range of cylinders spanning from +0.75D to +6.00D.

Teprotumumab (Tepezza, Amgen) receives marketing authorisation from MHRA

Teprotumumab (Tepezza, Amgen) receives marketing authorisation from MHRA

Kassi Filkins
May 8th 2025
Article

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

© 2025 MJH Life Sciences

All rights reserved.